ST6GAL1 and ovarian carcinoma: These reports were corroborated in an ovarian cancer model (OV4 and SKOV3 cell lines) which showed a direct correlation between EGFR activation and ST6Gal1 expression, further confirmed EGFR as substrate of ST6Gal1, and demonstrated that ST6Gal1-mediated sialylation of EGFR leads to gefitinib resistance (Britain et al., 2018).